The CA125 blood test is not an effective screening test when used alone, given that CA125 levels are only increased in 50% of stage I ovarian cancers and can also be increased in benign disorders, such as uterine fibroids, ovarian cysts and other conditions such as liver disease and infections [16, 17]. The gene discussed is MUC16; the disease is uterine corpus leiomyoma.